icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
eNrNWF1v2jAUfedXRHknLlm/mALVxtoNqdUYLdq0l8pJbsDM2Nm1Q+l+/RwCHZ0StTW11Eds59zre4+PD47OVgvuLQEVk6Lnd4ID3wORyJSJac+f3Fy0T/2zfiua0yXdWWbWBWHoewmnSvX8cjaIgQoV/Li6/ATme0C/3/IiGc8h0Y/WFZrx4AtVsyual2u8aClZ6i1Az2Ta8/NCr0e9SGk0WfTvJP5SOU0gIpuR3dn57eHueERKsGegFgrwkoppLSgIK8ykQAShB1TDVOJ9Q77vrLCZGoOSBSYwono2QrlkKaS1ITLKFVgFye7Sa8AlB10GqQUn82ShrMDpnK7G8HtYn/QHMzvQK90+aHdOOifhabd72D0M7ZqLO6Wq74LZBEluTaTj8DgkIMhcEc5iwhZ0CupSUlNckii1Hc8BM0NklaDkPKZIOsFqO9h+GA3myrK5I4mackdtZWrwmJmO4iD8fpI+KVM5p/emUrltqShSMw1o9MPdRsod3KBRNG5q9h++KDgnL8x6stEbRxmXcjaQhdANsnMxti3EQAoNq+aO2imlXm24yEC9HuwfKepviVERc5bYaqJRrQKUnoyHzZL4ptTkI1UwQXdy8p2JVN6p15epXVo4yj5fK20taI5p5zbsnh53jo6sT+FPw8GGO+68QJkDMQLG1D66NBSZ3FeRDK3robakfjt8Xls1mVAODWatbaluhshbb+nsqLg7htVELejn8xtbfn0rAO+v1z9roVnae2CGnfS7uE8MmxsTf/nZqCTCiY0vsF56Zlrn6j0hM6raipoKBRm+vXtlxwu4+wfixHBUBqzSZkepx9Wl+/z22h7Rp+zIvhZ78/3GytfG0FjAHn2o1NyZ5g7PX1/G//lrZ2mPHsmOuzBrL0w1k8KVxSriWsT9Lg7TV3GBRhy+ZhlreA1q5GVEqpeofisi5StUv/UX5GRCFw==
s35m30BV3Dv4TCWB